TABLE 3.
Sensitivity and Specificity of Anti-TRPS1 Antibodies
| TRPS1 MSVA-512R | TRPS1 EPR16171 | TRPS1 PA5-84874 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor entity | Category for sensitivity/specificity calculation | n | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | n | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | n | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | |
| Tumors of the skin | Basal cell carcinoma | Non-breast cancer | 14 | 100.0 | 0.0 | 0.0 | 0.0 | 26 | 38.5 | 57.7 | 3.8 | 0.0 | 25 | 52.0 | 36.0 | 12.0 | 0.0 |
| Squamous cell carcinoma of the skin | Non-breast cancer | 30 | 83.3 | 16.7 | 0.0 | 0.0 | 37 | 24.3 | 45.9 | 27.0 | 2.7 | 36 | 25.0 | 38.9 | 33.3 | 2.8 | |
| Tumors of the head and neck | Squamous cell carcinoma of the larynx | Non-breast cancer | 50 | 86.0 | 14.0 | 0.0 | 0.0 | 53 | 22.6 | 34.0 | 34.0 | 9.4 | 55 | 16.4 | 47.3 | 34.5 | 1.8 |
| Squamous cell carcinoma of the pharynx | Non-breast cancer | 49 | 65.3 | 30.6 | 4.1 | 0.0 | 55 | 25.5 | 32.7 | 32.7 | 9.1 | 57 | 24.6 | 33.3 | 35.1 | 7.0 | |
| Oral squamous cell carcinoma (floor of the mouth) | Non-breast cancer | 60 | 65.0 | 33.3 | 0.0 | 1.7 | 70 | 14.3 | 31.4 | 47.1 | 7.1 | 73 | 12.3 | 35.6 | 49.3 | 2.7 | |
| Tumors of the female genital tract | Squamous cell carcinoma of the vagina | Non-breast cancer | 28 | 89.3 | 7.1 | 3.6 | 0.0 | 28 | 46.4 | 35.7 | 7.1 | 10.7 | 28 | 53.6 | 32.1 | 3.6 | 10.7 |
| Squamous cell carcinoma of the vulva | Non-breast cancer | 74 | 89.2 | 10.8 | 0.0 | 0.0 | 74 | 20.3 | 37.8 | 31.1 | 10.8 | 75 | 16.0 | 44.0 | 25.3 | 14.7 | |
| Squamous cell carcinoma of the cervix | Non-breast cancer | 77 | 98.7 | 0.0 | 0.0 | 1.3 | 78 | 66.7 | 16.7 | 14.1 | 2.6 | 76 | 56.6 | 27.6 | 13.2 | 2.6 | |
| Carcinosarcoma of the uterus | Non-breast adenocarcinoma | 19 | 68.4 | 26.3 | 5.3 | 0.0 | 15 | 33.3 | 26.7 | 40.0 | 0.0 | 14 | 28.6 | 28.6 | 14.3 | 28.6 | |
| Endometrioid carcinoma of the ovary | Non-breast adenocarcinoma | 32 | 65.6 | 12.5 | 18.8 | 3.1 | 21 | 28.6 | 28.6 | 19.0 | 23.8 | 21 | 23.8 | 23.8 | 23.8 | 28.6 | |
| Serous carcinoma of the ovary | Non-breast adenocarcinoma | 79 | 58.2 | 25.3 | 13.9 | 2.5 | 71 | 25.4 | 26.8 | 21.1 | 26.8 | 70 | 18.6 | 30.0 | 15.7 | 35.7 | |
| Mucinous carcinoma of the ovary | Non-breast adenocarcinoma | 24 | 95.8 | 4.2 | 0.0 | 0.0 | 16 | 75.0 | 0.0 | 18.8 | 6.3 | 15 | 80.0 | 0.0 | 20.0 | 0.0 | |
| Clear cell carcinoma of the ovary | Non-breast adenocarcinoma | 21 | 85.7 | 4.8 | 9.5 | 0.0 | 16 | 25.0 | 31.3 | 31.3 | 12.5 | 16 | 43.8 | 25.0 | 18.8 | 12.5 | |
| Carcinosarcoma of the ovary | Non-breast adenocarcinoma | 17 | 76.5 | 17.6 | 5.9 | 0.0 | 12 | 41.7 | 25.0 | 16.7 | 16.7 | 10 | 30.0 | 40.0 | 10.0 | 20.0 | |
| Tumors of the breast | Invasive breast carcinoma of no special type | Breast cancer | 462 | 19.7 | 7.8 | 26.6 | 45.9 | 422 | 5.5 | 5.5 | 9.0 | 80.1 | 430 | 6.0 | 8.4 | 5.3 | 80.2 |
| Lobular carcinoma of the breast | Breast cancer | 142 | 10.6 | 6.3 | 31.0 | 52.1 | 118 | 2.5 | 4.2 | 9.3 | 83.9 | 119 | 3.4 | 4.2 | 4.2 | 88.2 | |
| Medullary carcinoma of the breast | Breast cancer | 8 | 0.0 | 25.0 | 25.0 | 50.0 | 7 | 0.0 | 0.0 | 14.3 | 85.7 | 7 | 0.0 | 0.0 | 14.3 | 85.7 | |
| Tubular carcinoma of the breast | Breast cancer | 2 | 0.0 | 0.0 | 50.0 | 50.0 | 2 | 0.0 | 0.0 | 0.0 | 100.0 | 2 | 0.0 | 0.0 | 0.0 | 100.0 | |
| Mucinous carcinoma of the breast | Breast cancer | 6 | 0.0 | 0.0 | 33.3 | 66.7 | 6 | 0.0 | 0.0 | 0.0 | 100.0 | 7 | 0.0 | 0.0 | 0.0 | 100.0 | |
| Hormone receptor-positive breast cancer * | — | 425 | 16.9 | 7.1 | 28.0 | 48.0 | 402 | 3.0 | 3.5 | 8.2 | 85.3 | 410 | 3.7 | 5.9 | 4.9 | 85.6 | |
| Triple-negative breast cancer * | Triple-negative breast cancer | 58 | 32.8 | 17.2 | 22.4 | 27.6 | 58 | 13.8 | 15.5 | 10.3 | 60.3 | 59 | 13.6 | 20.3 | 5.1 | 61.0 | |
| Tumors of the digestive system | Adenocarcinoma of the colon | Non-breast adenocarcinoma | 79 | 100.0 | 0.0 | 0.0 | 0.0 | 69 | 94.2 | 5.8 | 0.0 | 0.0 | 70 | 94.3 | 5.7 | 0.0 | 0.0 |
| Gastric adenocarcinoma, diffuse type | Non-breast adenocarcinoma | 67 | 100.0 | 0.0 | 0.0 | 0.0 | 40 | 75.0 | 15.0 | 10.0 | 0.0 | 43 | 86.0 | 4.7 | 2.3 | 7.0 | |
| Gastric adenocarcinoma, intestinal type | Non-breast adenocarcinoma | 69 | 95.7 | 2.9 | 1.4 | 0.0 | 42 | 54.8 | 33.3 | 2.4 | 9.5 | 42 | 52.4 | 35.7 | 4.8 | 7.1 | |
| Adenocarcinoma of the esophagus | Non-breast adenocarcinoma | 70 | 98.6 | 0.0 | 0.0 | 1.4 | 43 | 58.1 | 23.3 | 16.3 | 2.3 | 45 | 57.8 | 24.4 | 8.9 | 8.9 | |
| Squamous cell carcinoma of the esophagus | Non-breast cancer | 61 | 91.8 | 8.2 | 0.0 | 0.0 | 39 | 15.4 | 46.2 | 23.1 | 15.4 | 35 | 25.7 | 40.0 | 22.9 | 11.4 | |
| Squamous cell carcinoma of the anal canal | Non-breast cancer | 30 | 80.0 | 20.0 | 0.0 | 0.0 | 37 | 5.4 | 54.1 | 35.1 | 5.4 | 38 | 5.3 | 34.2 | 44.7 | 15.8 | |
| Ductal adenocarcinoma of the pancreas | Non-breast adenocarcinoma | 80 | 98.8 | 1.3 | 0.0 | 0.0 | 64 | 79.7 | 14.1 | 6.3 | 0.0 | 68 | 82.4 | 14.7 | 2.9 | 0.0 | |
| Pancreatic/ampullary adenocarcinoma | Non-breast adenocarcinoma | 28 | 100.0 | 0.0 | 0.0 | 0.0 | 23 | 78.3 | 17.4 | 4.3 | 0.0 | 23 | 87.0 | 13.0 | 0.0 | 0.0 | |
| Acinar cell carcinoma of the pancreas | Non-breast adenocarcinoma | 5 | 100.0 | 0.0 | 0.0 | 0.0 | 4 | 75.0 | 25.0 | 0.0 | 0.0 | 4 | 75.0 | 0.0 | 25.0 | 0.0 | |
| Tumors of the male genital organs | Adenocarcinoma of the prostate, Gleason 3+3 | Non-breast adenocarcinoma | 78 | 100.0 | 0.0 | 0.0 | 0.0 | 64 | 84.4 | 10.9 | 4.7 | 0.0 | 65 | 96.9 | 3.1 | 0.0 | 0.0 |
| Adenocarcinoma of the prostate, Gleason 4+4 | Non-breast adenocarcinoma | 69 | 100.0 | 0.0 | 0.0 | 0.0 | 55 | 45.5 | 27.3 | 27.3 | 0.0 | 57 | 71.9 | 19.3 | 8.8 | 0.0 | |
| Adenocarcinoma of the prostate, Gleason 5+5 | Non-breast adenocarcinoma | 79 | 96.2 | 3.8 | 0.0 | 0.0 | 67 | 20.9 | 52.2 | 17.9 | 9.0 | 62 | 62.9 | 22.6 | 8.1 | 6.5 | |
| Squamous cell carcinoma of the penis | Non-breast cancer | 55 | 87.3 | 9.1 | 3.6 | 0.0 | 72 | 30.6 | 23.6 | 30.6 | 15.3 | 71 | 15.5 | 39.4 | 36.6 | 8.5 | |
| Breast cancers vs non-breast adenocarcinomas | Sensitivity | 0.83 | Sensitivity | 0.95 | Sensitivity | 0.95 | |||||||||||
| Specificity | 0.92 | Specificity | 0.58 | Specificity | 0.67 | ||||||||||||
| Breast cancers vs non-breast adenocarcinomas/non-breast cancers | Sensitivity | 0.83 | Sensitivity | 0.95 | Sensitivity | 0.95 | |||||||||||
| Specificity | 0.89 | Specificity | 0.44 | Specificity | 0.47 | ||||||||||||
| Triple-negative breast cancers vs non-breast adenocarcinomas | Sensitivity | 0.76 | Sensitivity | 0.86 | Sensitivity | 0.86 | |||||||||||
| Specificity | 0.92 | Specificity | 0.58 | Specificity | 0.67 | ||||||||||||
| Triple-negative breast cancers vs non-breast adenocarcinomas/non-breast cancers | Sensitivity | 0.76 | Sensitivity | 0.86 | Sensitivity | 0.86 | |||||||||||
| Specificity | 0.89 | Specificity | 0.44 | Specificity | 0.47 | ||||||||||||
*Included in the other subtypes of breast cancers.